Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Reprogramming alveolar macrophage responses to TGF-β reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndrome
Zhiyi Liu, … , Yongjian Liu, Andrew E. Gelman
Zhiyi Liu, … , Yongjian Liu, Andrew E. Gelman
Published October 3, 2022
Citation Information: J Clin Invest. 2022;132(19):e159229. https://doi.org/10.1172/JCI159229.
View: Text | PDF
Research Article Immunology Inflammation

Reprogramming alveolar macrophage responses to TGF-β reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndrome

  • Text
  • PDF
Abstract

Bronchiolitis obliterans syndrome (BOS) is a major impediment to lung transplant survival and is generally resistant to medical therapy. Extracorporeal photophoresis (ECP) is an immunomodulatory therapy that shows promise in stabilizing BOS patients, but its mechanisms of action are unclear. In a mouse lung transplant model, we show that ECP blunts alloimmune responses and inhibits BOS through lowering airway TGF-β bioavailability without altering its expression. Surprisingly, ECP-treated leukocytes were primarily engulfed by alveolar macrophages (AMs), which were reprogrammed to become less responsive to TGF-β and reduce TGF-β bioavailability through secretion of the TGF-β antagonist decorin. In untreated recipients, high airway TGF-β activity stimulated AMs to express CCL2, leading to CCR2+ monocyte-driven BOS development. Moreover, we found TGF-β receptor 2–dependent differentiation of CCR2+ monocytes was required for the generation of monocyte-derived AMs, which in turn promoted BOS by expanding tissue-resident memory CD8+ T cells that inflicted airway injury through Blimp-1–mediated granzyme B expression. Thus, through studying the effects of ECP, we have identified an AM functional plasticity that controls a TGF-β–dependent network that couples CCR2+ monocyte recruitment and differentiation to alloimmunity and BOS.

Authors

Zhiyi Liu, Fuyi Liao, Jihong Zhu, Dequan Zhou, Gyu Seong Heo, Hannah P. Leuhmann, Davide Scozzi, Antanisha Parks, Ramsey Hachem, Derek E. Byers, Laneshia K. Tague, Hrishikesh S. Kulkarni, Marlene Cano, Brian W. Wong, Wenjun Li, Howard J. Huang, Alexander S. Krupnick, Daniel Kreisel, Yongjian Liu, Andrew E. Gelman

×

Figure 1

ECP prevents BOS and lymphocyte recognition of transplant antigens.

Options: View larger image (or click on image) Download as PowerPoint
ECP prevents BOS and lymphocyte recognition of transplant antigens.
(A) ...
(A) 3T-FVB left lungs were transplanted into C57BL/6 (B6) mice and treated with CD40L Abs (POD0) and CTLA4 Ig (POD2) to establish allograft tolerance. Between POD7 and POD9, recipients ingested DOX. They received saline or ECP-treated B6 leukocytes on POD9, POD12, and POD15 and were euthanized on POD16. (B) Representative allograft H&E, trichrome, and CCSP/Ac-tubulin Ab staining. Images shown are representative of n = 10/group. Allografts scored for airway inflammation (C) (B score) and (D) the presence (designated 1) or absence (designated 0) of OB lesions (C score) (n = 10/group). Intragraft (E) total (n = 5/group) and (F) Ki67+ club cell numbers (n = 5/group) and (G) hydroxyproline content (n = 6/group). (H) Intragraft neutrophil numbers (n = 6/group). (I) Representative FACS plots of the intragraft percentage of abundance for indicated T lymphocyte lineages (n = 5/group). (J–L) T cell antigen specificity measured by IFN-γ and IL-17A production following stimulation with splenocytes isolated from B6 (syngeneic antigens), FVB (donor antigens), or B6 mice pulsed with lung self-antigens Col V and Kα1T (n = 5/group). (M) DSA (IgM) serum reactivity against FVB CD19+ cells at indicated dilutions (n = 10/group). Assay data shown for G and J–L are representative of at least 2 independent evaluations. Data are represented as mean ± SD. Two-sided Mann Whitney U test (C–H and J–M). *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts